Clinical trials: Rhinoconjunctivitis
Allergy
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
- Trial name
- NCT01353079
- Testing
- Short Ragweed Pollen Allergenic Extract
- Where
- United States
- Volunteers
- 429 people
- Sponsor
- Greer Laboratories
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics
Grass Pollen Allergy, Hay Fever
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT01308021
- Testing
- gpASIT+TM
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 202 people
- Sponsor
- BioTech Tools S.A.
Grass Pollen Induced Allergic Rhinoconjunctivitis
Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
The clinical trial will investigate the efficacy of Avanz Phleum pratense in the treatment of rhinitis in an environmental challenge chamber.
- Trial name
- AV-G-03 (NCT02166268)
- Testing
- AVANZ Phleum pratense 15,000 SQ+
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis
Open Label Safety Study of a Birch Pollen Allergen Extract
This trial is performed to assess safety of a sublingual birch pollen extract.
- Trial name
- NCT00818181
- Testing
- Biological: AL0206st
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against grass pollen allergy
- Trial name
- MG56 (NCT02654223)
- Testing
- MG56 Mannosylated 500 subcutaneous, MG56 Mannosylated 1000 subcutaneous, MG56 Mannosylated 3000 subcutaneous
- Where
- 12 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen
An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy
This trial is an open, national, multi-centre trial. The trial will be initiated in December 2013 and subjects will receive treatment for 6 weeks.
- Trial name
- AV-X-02 (NCT02065856)
- Testing
- AVANZ Salsola
- Where
- Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis
House Dust Mite Observational Study
A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis
- Trial name
- NCT01949428
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Circassia Limited
Rhinitis, Allergic, Rhinoconjunctivitis
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or…
- Trial name
- ARES (NCT03821077)
- Testing
- Allergen Immunotherapy (AIT)
- Where
- 10 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Roxall Medicina España S.A
Allergy
A Trial of the ALK Grass Tablet in Subjects With Hayfever
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
- Trial name
- NCT00227279
- Testing
- ALK Grass tablet
- Where
- Denmark
- Volunteers
- 634 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinitis
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen
The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerised with glutaraldehyde)of the subcutaneous injection of Phleum pratense pollen in the treatment of patients affected…
- Trial name
- NCT00916422
- Testing
- Allergen extract (Phleum pratense)
- Where
- 23 sites in Hungary, Spain
- Volunteers
- 153 people
- Sponsor
- Laboratorios Leti, S.L.
Seasonal Allergic Rhinitis, Hay Fever
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
Evaluate the relative efficacy of four dosing regimens of bilastine tablets (given either once or twice per day) versus placebo in patients with Seasonal Allergic Rhinitis (SAR) in the Mountain Cedar season in south Texas and…
- Conditions
- Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
- Trial name
- NCT00574379
- Testing
- Bilastine
- Where
- 13 sites in United States
- Volunteers
- 805 people
- Sponsor
- Faes Farma, S.A.
Ragweed Allergy
Ragweed Observational Study
This is an observational to evaluate Total Rhinoconjunctivitis Symptom Score and rescue medication usage (as measured by Rescue Medication Score as a Combined Score to inform the design of a phase III field study with ToleroMune…
- Trial name
- NCT01398137
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
The goal of this pilot study is to develop an eye allergen challenge model, called a conjunctival allergen challenge (CAC), using timothy grass as the allergen.
- Trial name
- INQUIRE (NCT07801625)
- Testing
- Standardized Allergen Extract, Timothy Grass (Phleum pratense)
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dr. Anne Ellis
Allergic Rhinoconjunctivitis
Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract
As part of the registration plan of our products and after performing a Phase I study the present trial has been designed to compare the efficacy of 5 different doses of subcutaneous immunotherapy in depot presentation.
- Trial name
- NCT01564017
- Testing
- Allergovac depot
- Where
- 12 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Roxall Medicina España S.A
Allergic Rhinoconjunctivitis
Nasal Mucus Proteome and Immunotherapy
Nasal mucus as first line defense barrier of the nasal mucosa contains a variety of proteins that act as functional units. We recently showed that the nasal mucus proteome between allergic rhinitis patients and healthy controls…
- Trial name
- NCT02159404
- Testing
- Immunotherapy
- Where
- Austria
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Allergy
Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis
To find a test to elaborate a parameter for specific immunotherapy in allergic patients
- Trial name
- NCT00461721
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
Cat Allergy
Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel, synthetic, allergen derived peptide desensitising vaccine currently being developed for…
- Trial name
- NCT01383603
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Circassia Limited
Rhinoconjunctivitis
A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica
The study was designed according to the draft of allergenic product regulation published by Spanish Regulatory Agency. The aim of the study is to evaluate the safety and tolerability of subcutaneous immunotherapy with Parietaria…
- Trial name
- NCT02477917
- Testing
- Allergovac depot with Parietaria judaica pollen extract
- Where
- 4 sites in Spain
- Volunteers
- 51 people
- Sponsor
- Roxall Medicina España S.A